Autoimmune disease

Laboratory research
#Autoimmune disease #Inflammatory diseases #Nimbus #Phase I trial

First-in-class SIK2 inhibitor enters Phase I trial

Nimbus Therapeutics has dosed the first subjects in its Phase I clinical trial of NDI-225673, a highly selective inhibitor of salt-inducible kinase 2 (SIK2) for the potential treatment of immune-mediated inflammatory diseases.   The Phase I trial is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and… Read More

#News

IgG1 monoclonal antibody
#Autoimmune disease #Phase I trial #Therapeutic Antibodies #Viridian Therapeutics

FcRn inhibitor demonstrates sustained IgG reduction in Phase I trial

Viridian Therapeutics has announced positive Phase I trial results for VRDN-008, a half-life extended bifunctional FcRn inhibitor licensed from Paragon Therapeutics.  In the trial, VRDN-008 demonstrated a potential best-in-class pharmacokinetic (PK) and pharmacodynamic (PD) profile with the potential to be dosed every eight weeks.   VRDN-008… Read More

#News

CAR-T therapy
#Allogene Therapeutics #Autoimmune disease #CAR-T #Cell therapy #Phase I trial

First clinical data for allogeneic CAR-T in autoimmune disease

Allogene Therapeutics has reported preliminary safety, efficacy and translational data from the ongoing Phase I RESOLUTION study evaluating ALLO-329, an investigational, off-the-shelf allogeneic CAR-T product designed specifically for autoimmune disease.   The data were presented at the American College of Rheumatology (ACR) Convergence in Orlando, Florida. … Read More

#Editor's Choice #News

Vaccine research
#Autoimmune disease #Ion channel modulators #Phase I trial #Zealand Pharma

Ion channel blocker for autoimmune disease well tolerated in trial

Zealand Pharma has shared positive Phase I multiple ascending dose (MAD) topline results for the company’s novel Kv1.3 ion channel blocker, ZP9830.  The MAD part of the first-in-human, single-centre, randomised, double-blind, placebo-controlled Phase I trial was designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple… Read More

#News

FDA
#Autoimmune disease #FDA #Genentech

FDA approves obinutuzumab for rare autoimmune disease

The US Food and Drug Administration (FDA) has given the go-ahead to Genentech’s Gazyva (obinutuzumab) in adult and paediatric patients two years of age and older.  It is approved to reduce the risk of relapse in patients with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome (INS) who are… Read More

#News #Regulatory

handshake
#Autoimmune disease #Eli Lilly #Immunology #Mergers and acquisitions

Merida acquisition strengthens Lilly’s immunology capabilities

Eli Lilly has announced plans to acquire Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases.  Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies, the disease-causing agents behind a range of immune-mediated conditions.   The precision degradation approach is intended… Read More

#Business & Investment #News #Trending News

Bispecific antibodies
#Autoimmune disease #Bi- and trispecifics #Mergers and acquisitions #Roche

Roche acquires trispecific antibody for $1.5bn

Roche has acquired exclusive global rights to develop, manufacture, and commercialise SIM0660, a trispecific antibody targeting CD79a, CD19, and CD3, with therapeutic potential across B-cell-mediated diseases.  Under the terms of the agreement, developer Simcere Zaiming is eligible to receive up to $1.530 billion in total payments, including $75 million in… Read More

#Business & Investment #News

#Autoimmune disease #Collaboration #Evotec #Inflammatory diseases #Odyssey Therapeutics

Evotec joins Odyssey in autoimmune drug development

Evotec has entered a strategic R&D collaboration with Odyssey Therapeutics to discover potential new treatments in autoimmune and inflammatory diseases.  Under the agreement, Odyssey will use Evotec's data-driven discovery platform, screening capabilities and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across multiple high-value disease… Read More

#Business & Investment #News

Antibodies
#Autoimmune disease #Kira Pharmaceuticals #Mergers and acquisitions #Mirador Therapeutics

Mirador Therapeutics licenses anti-C5a antibody from Kira Pharmaceuticals

Mirador Therapeutics has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a potentially long-acting, sweeping anti-C5a antibody designed to inhibit C5a/C5aR-mediated inflammation.   The agreement expands Mirador’s precision immunology portfolio into inflammatory vascular disease. Kira will receive $12 million upon signing.  The C5a/C5aR axis is clinically and… Read More

#Business & Investment #News

#Autoimmune disease #etherna #mRNA #Multiple sclerosis #Type 1 diabetes

mRNA technology could treat autoimmune diseases, study shows

mRNA technology could help treat autoimmune diseases such as multiple sclerosis and type 1 diabetes, researchers say.  Scientists at the Biomedical Research Institute (BIOMED) at Hasselt University and the Belgian biotech company etherna have demonstrated that mRNA technology, which gained recognition for its use in Covid-19 vaccines, also holds promise for the targeted… Read More

#Editor's Choice #News

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

This week in Drug Discovery (18 – 22 May)

News round-up for 18 – 22 May by Bruno Quinney, Content Team at DDW.    This week, a report showed patients in Europe face barriers to patient access. Elsewhere, Wellcome prizes are facilitating research in both tropical disease and mental health.    The… Read More

#News

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

DDW Highlights: 19 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research uncovered new treatment pathways for hard to treat breast cancers. Elsewhere,… Read More

#Podcasts

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

This week in Drug Discovery (11 – 15 May) 

News round-up for 11 – 15 May by Bruno Quinney, Content Team at DDW.  This week, research has uncovered new treatment pathways for hard to treat breast cancers. Elsewhere, therapies given the green light could combat type 2 diabetes and generalised myasthenia gravis.  The top stories:   … Read More

#News

#Autoimmune disease #Clinical trial #FDA

FDA treatment approval brings ‘hope’ to gMG patients 

The US Food and Drug Administration (FDA) has approved the first treatments for all serotypes of patients living with generalised myasthenia gravis (gMG).  The FDA’s label expansion of Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) now means gMG adult patients can treat all serotypes, including anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative. … Read More

#News #Regulatory

Handshake jigsaw puzzle
#Autoimmune disease #Genomics #T cell

Genomics and Greywolf partner on autoimmune disease treatments 

Techbio company Genomics has partnered with biotech company Greywolf Therapeutics to advance novel antigen modulation treatments to treat autoimmune diseases.  Under the agreement, Genomics is set to curate and analyse large-scale genetic datasets to assess how variants of the ERAP (Endoplasmic Reticulum Aminopeptidases) enzymes influence disease risk across multiple autoimmune conditions. … Read More

#Business & Investment #News

#Autoimmune disease #National Institute for Health and Care Excellence (NICE) #UCB

NICE recommends Rystiggo for rare autoimmune disease 

The National Institute for Health and Care Excellence (NICE) has recommended Rystiggo (rozanolixizumab) as a treatment for adults with antibody-positive generalised myasthenia gravis (gMG).  Rystiggo is the first targeted therapy for gMG, a rare, chronic autoimmune neuromuscular disease. The condition is characterised by fluctuating muscle weakness and fatigue and can lead to difficulties with vision,… Read More

#News